Royalty Pharma
RPRX
283 hedge funds and large institutions have $12.2B invested in Royalty Pharma in 2022 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 108 increasing their positions, 81 reducing their positions, and 44 closing their positions.
1,273% more call options, than puts
Call options by funds: $75.8M | Put options by funds: $5.52M
33% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 81
18% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 44
16% more capital invested
Capital invested by funds: $10.5B → $12.2B (+$1.71B)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
4.4% more ownership
Funds ownership: 62.46% → 66.86% (+4.4%)
1% more funds holding
Funds holding: 279 → 283 (+4)
Top Buyers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$691M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$318M |
| 3 |
JP Morgan Chase
New York
|
+$85.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$80.7M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$65.8M |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$333M |
| 2 |
Morgan Stanley
New York
|
-$81.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$73.7M |
| 4 |
VCG
Vantage Consulting Group
Virginia Beach,
Virginia
|
-$68.7M |
| 5 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$58.3M |
RPRX Hedge Fund Activity: Q2 2022 in Review
283 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2022, worth a combined $12.2B — up 16% from $10.5B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new RPRX positions and 44 closed out — a net gain of 8 holders — while 108 added to existing stakes and 81 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $691M. The largest seller was Adage Capital Partners, cutting an estimated $333M.
- 283 institutional investors held Royalty Pharma (RPRX) as of Q2 2022, up from 279 in Q1 2022.
- Funds reported $12.2B of Royalty Pharma stock for Q2 2022, up 16% quarter-over-quarter.
- 52 funds opened new Royalty Pharma positions in Q2 2022 and 44 closed out, a net change of +8 holders.
- The largest Royalty Pharma buyer in Q2 2022 was Baillie Gifford & Co, an estimated $691M added.
- The largest Royalty Pharma seller in Q2 2022 was Adage Capital Partners, an estimated $333M sold.
Based on aggregated 13F filings for Q2 2022.